Trade Virpax Pharmaceuticals, Inc. - VRPX CFD
Add to favourite- Summary
- Historical Data
Spread | 0.16 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 3.23 |
Open | 2.98 |
1-Year Change | 319.72% |
Day's Range | 2.84 - 2.98 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 25, 2024 | 2.84 | -0.14 | -4.70% | 2.98 | 2.98 | 2.84 |
Apr 24, 2024 | 3.23 | 0.00 | 0.00% | 3.23 | 3.23 | 3.23 |
Apr 23, 2024 | 3.12 | -0.09 | -2.80% | 3.21 | 3.26 | 2.98 |
Apr 22, 2024 | 3.30 | 0.10 | 3.12% | 3.20 | 3.47 | 3.20 |
Apr 19, 2024 | 3.49 | -0.34 | -8.88% | 3.83 | 3.83 | 3.49 |
Apr 18, 2024 | 3.88 | 0.61 | 18.65% | 3.27 | 3.93 | 3.23 |
Apr 17, 2024 | 3.42 | 0.16 | 4.91% | 3.26 | 3.42 | 3.26 |
Apr 16, 2024 | 3.33 | 0.00 | 0.00% | 3.33 | 3.33 | 3.33 |
Apr 15, 2024 | 3.23 | 0.00 | 0.00% | 3.23 | 3.23 | 3.23 |
Apr 12, 2024 | 3.42 | 0.04 | 1.18% | 3.38 | 3.42 | 3.26 |
Apr 9, 2024 | 3.59 | 0.21 | 6.21% | 3.38 | 3.59 | 3.37 |
Apr 8, 2024 | 3.68 | 0.11 | 3.08% | 3.57 | 3.77 | 3.57 |
Apr 5, 2024 | 3.68 | -0.26 | -6.60% | 3.94 | 3.94 | 3.68 |
Apr 4, 2024 | 3.94 | -0.04 | -1.01% | 3.98 | 3.99 | 3.94 |
Apr 3, 2024 | 4.09 | 0.05 | 1.24% | 4.04 | 4.18 | 4.04 |
Apr 2, 2024 | 4.06 | -0.05 | -1.22% | 4.11 | 4.11 | 3.96 |
Apr 1, 2024 | 3.98 | -0.04 | -1.00% | 4.02 | 4.02 | 3.97 |
Mar 28, 2024 | 4.12 | 0.24 | 6.19% | 3.88 | 4.22 | 3.88 |
Mar 26, 2024 | 3.76 | 0.05 | 1.35% | 3.71 | 3.88 | 3.71 |
Mar 25, 2024 | 3.70 | -0.08 | -2.12% | 3.78 | 3.88 | 3.68 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Virpax Pharmaceuticals, Inc. Company profile
Founded in 2016, Virpax Pharmaceuticals (VRPX) is a preclinical stage biopharmaceutical company that develops and manufactures novel and proprietary drug delivery systems for non-opioid and non-addictive pain treatments.
Based in Berwyn, Pennsylvania, US, Virpax has global rights to the following patented pain management technologies:
Epoladerm – A topical nonsteroidal anti-inflammatory drug candidate for treatment of chronic osteoarthritis of the knee. It is used once a day.
Probudur – Injectable local anaesthetic Lipoal Gel Technology for postoperative pain management. The company plans to market this drug candidate to general surgeons, anesthesiologists and orthopaedic surgeons with the local anaesthetic postsurgical market, valued at $577m (£451m) as of 2019. The company believes Probudur can eliminate the need for opioids for postoperative pain relief.
Envelta – A Molecular Envelope Technology (MET) that delivers enkephalin for the management of acute and chronic pain, including cancer-induced pain, using an intranasal device. Virpax has identified a significant unmet need and market opportunity for current opioid prescribers, such as pain and hospice treatment centres.
AnQlar – A nasal spray that is being developed as an anti-viral barrier to potentially prevent or reduce the severity of viral infections in humans. The company has completed toxicology and ex-vivo studies on AnQlar, which show a reduction in infectivity from respiratory viruses such as influenza and SARS-CoV-2.
VRP324 – An investigational formulation designed to improve cannabidiol (CBD) transport to the brain via the nasal route. VRP324 propels the CBD powder formulation into the nose and into the brain via the olfactory nerve/bulb using a preassembled device and cartridge. This product candidate can potentially treat seizures associated with tuberous sclerosis complex (TSC), Lennox-Gastaut syndrome and Dravet syndrome in patients aged one year and older. CBD is a substance found in cannabis.
Virpax went public on 16 February 2021. Its stock is listed on the Nasdaq capital market under the ticker symbol ‘VRPX’.
Industry: | Biotechnology & Medical Research (NEC) |
1055 Westlakes Drive, Suite 300
BERWYN
PENNSYLVANIA 19312
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com